Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt to Equity (2016 - 2021)

Historic Debt to Equity for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q1 2021 value amounting to $0.0.

  • Lineage Cell Therapeutics' Debt to Equity changed N/A to $0.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $0.0, marking a year-over-year change of. This contributed to the annual value of $0.01 for FY2020, which is N/A changed from last year.
  • Lineage Cell Therapeutics' Debt to Equity amounted to $0.0 in Q1 2021.
  • In the past 5 years, Lineage Cell Therapeutics' Debt to Equity registered a high of $0.01 during Q3 2020, and its lowest value of $0.0 during Q4 2017.
  • Over the past 3 years, Lineage Cell Therapeutics' median Debt to Equity value was $0.0 (recorded in 2021), while the average stood at $0.0.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Debt to Equity was 7101.49% (2017), while the steepest drop was 8808.24% (2017).
  • Lineage Cell Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2017, then surged by 4861.33% to $0.01 in 2020, then dropped by 18.25% to $0.0 in 2021.
  • Its Debt to Equity stands at $0.0 for Q1 2021, versus $0.01 for Q4 2020 and $0.01 for Q3 2020.